Receptor density and recycling affect the rate of agonist-induced desensitization of mu-opioid receptor

P Y Law1, L J Erickson, R El-Kouhen

  • 1Department of Pharmacology, 6-120 Jackson Hall, University of Minnesota, Minneapolis, Minnesota 55455, USA. Ping@mail.ahc.umn.edu

Insights

Mu-opioid receptor (MOR) desensitization is slowed by receptor resensitization and recycling. Blocking these processes, particularly receptor internalization, enhances MOR desensitization rates in human embryonic kidney (HEK)293 and SHSY5Y cells.

Area of Science:

  • Pharmacology
  • Cell Biology
  • Neuroscience

Background:

  • Mu-opioid receptor (MOR) phosphorylation kinetics do not correlate with its desensitization rate.
  • Controversy exists regarding whether receptor phosphorylation triggers MOR desensitization.

Purpose of the Study:

  • To investigate the mechanisms underlying the slow desensitization rate of MOR.
  • To determine the roles of receptor recycling and resensitization in MOR desensitization.

Main Methods:

  • Utilized human embryonic kidney (HEK)293 and human neuroblastoma SHSY5Y cells expressing MOR.
  • Employed fluorescence-activated cell-sorting analysis to assess receptor recycling.
  • Used monensin, brefeldin A, beta-furnaltrexamine (betaFNA), and sucrose to manipulate cellular processes and receptor levels.
  • Measured adenylyl cyclase activity to assess receptor desensitization.

Main Results:

  • Receptor desensitization rate is partially attributed to the recycling of internalized MOR.
  • Reducing MOR levels with betaFNA significantly increased desensitization rates.
  • Blocking receptor internalization with sucrose enhanced rapid desensitization in betaFNA-treated cells.
  • In SHSY5Y cells, blocking internalization enhanced desensitization, while monensin prevented resensitization.

Conclusions:

  • Mu-opioid receptor resensitization and recycling contribute significantly to the slow observed desensitization rate.
  • The efficiency of MOR in regulating adenylyl cyclase activity also influences desensitization kinetics.
  • Understanding these mechanisms is crucial for developing targeted opioid-based therapies.

Related Concept Videos

Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
Spare Receptors01:30

Spare Receptors

Some receptors remain unoccupied even when an agonist produces a maximal response. Such empty ones are called spare receptors. In presence of spare receptors the maximum effect of an agonist drug is achieved with fewer than 100% of the receptors being occupied. To determine the presence of spare receptors, scientists often compare the concentration of the drug needed to produce 50% of the maximum effect (EC50) with the concentration of the drug needed to occupy 50% of the receptors (Kd). If the...
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...